Skip to main content

We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.

Join Now
Sign In

Member Sign In

Username or Email Address

Password

Keep Me Signed In What does "Remember Me" do?

Don't Know Your Password?
Help

Join Now
Sign In

Member Sign In

Username or Email Address

Password

Keep Me Signed In

Don't Know Your Password?

Zacks

more

Genocea Biosciences, Inc. (GNCA)

(Delayed Data from NSDQ)

$0.70 USD

+0.01 (0.73%)

Updated May 3, 2019 04:13 PM ET

After-Market: $0.70 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.15%
2	Buy	17.88%
3	Hold	9.47%
4	Sell	5.14%
5	Strong Sell	2.57%
S&P	500	11.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

NA

View All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

Genocea Biosciences, Inc. [GNCA]

Reports for Purchase

Showing records 1 - 20 ( 46 total )

Company: Genocea Biosciences, Inc.

Industry: Medical - Drugs

Record: 1

06/09/2022

Pages: 5

Dropping coverage on operations wind-down.

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 5.00

Research Provided by a Third Party

Company: Genocea Biosciences, Inc.

Industry: Medical - Drugs

Record: 2

04/29/2022

Pages: 7

Company Hunkers Down and So Do We; Downgrade to Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Genocea Biosciences, Inc.

Industry: Medical - Drugs

Record: 3

04/11/2022

Pages: 7

AACR Highlights GEN-011''s Early Glimpse at Activity in Difficult to Treat Tumors

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Genocea Biosciences, Inc.

Industry: Medical - Drugs

Record: 4

03/10/2022

Pages: 6

2021 Results; TiTAN Looks to Walk Tall; GEN-011 Update at AACR

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Genocea Biosciences, Inc.

Industry: Medical - Drugs

Record: 5

01/04/2022

Pages: 4

ATLAS Piques Interest From Janssen; GEN-011 Programs Pushes Forward With Data Expected in 1H22

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 5.00

Research Provided by a Third Party

Company: Genocea Biosciences, Inc.

Industry: Medical - Drugs

Record: 6

10/28/2021

Pages: 6

3Q21 Results; TiTAN Stays on Track; Pipeline Visibility Increases with SITC Presentations

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Genocea Biosciences, Inc.

Industry: Medical - Drugs

Record: 7

09/28/2021

Pages: 10

ValuEngine Detailed Valuation Report for GNCA

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Genocea Biosciences, Inc.

Industry: Medical - Drugs

Record: 8

07/29/2021

Pages: 6

2Q21 Results; GEN-011 and GEN-009 Momentum Builds; Updates Expected Throughout Year

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Genocea Biosciences, Inc.

Industry: Medical - Drugs

Record: 9

07/13/2021

Pages: 4

TiTAN Takes a Giant Step Forward; First Patient Dosed in Phase 1/2a Trial

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Genocea Biosciences, Inc.

Industry: Medical - Drugs

Record: 10

06/07/2021

Pages: 9

Promising Long-Term GEN-009 Data at ASCO

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Genocea Biosciences, Inc.

Industry: Medical - Drugs

Record: 11

04/29/2021

Pages: 6

1Q21 Results; GEN-009 and GEN-011 Stay the Course; Upcoming Data at ASCO

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Genocea Biosciences, Inc.

Industry: Medical - Drugs

Record: 12

02/11/2021

Pages: 6

2020 Results; Progress Continues in Two Key Clinical Programs; COVID Entering Fray?

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Genocea Biosciences, Inc.

Industry: Medical - Drugs

Record: 13

11/10/2020

Pages: 9

Another Piece to the GEN-009 Puzzle; Watching the Curves Shift

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Genocea Biosciences, Inc.

Industry: Medical - Drugs

Record: 14

10/29/2020

Pages: 6

3Q20 Results; Rapidly Approaching Important Show-Me Stage for GEN-009 as GEN-011 Program Gets Going

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Genocea Biosciences, Inc.

Industry: Medical - Drugs

Record: 15

09/17/2020

Pages: 6

GEN-009 Data Continue to Look Encouraging; Key Updates Expected Later This Year

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Genocea Biosciences, Inc.

Industry: Medical - Drugs

Record: 16

09/03/2020

Pages: 5

Next GEN-009 Update Solidified For ESMO, But Larger Disclosure Later This Year Likely A Bigger Catalyst

Provider: Stifel Nicolaus Co., Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Genocea Biosciences, Inc.

Industry: Medical - Drugs

Record: 17

07/30/2020

Pages: 8

Intriguing First Look From Part B; Broader Look in September

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Genocea Biosciences, Inc.

Industry: Medical - Drugs

Record: 18

07/23/2020

Pages: 8

2Q20 Results; Eyes on Part B Data Next Week; Target Reduced to $9

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Genocea Biosciences, Inc.

Industry: Medical - Drugs

Record: 19

07/20/2020

Pages: 5

Next Important GEN-009 Data Shortly; GEN-011 IND Discussions Remain Ongoing; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Genocea Biosciences, Inc.

Industry: Medical - Drugs

Record: 20

06/23/2020

Pages: 7

ATLAS'' Differentiated Profile Gets Another Big Boost

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

previous
1
2
3
next